News | June 04, 2022
RH Capital announces investments to improve women’s health
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Facility features LED lighting, solar panels, automation and innovative temperature-controlled systems to maximize efficiency and minimize environmental impact
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Subscribe To Our Newsletter & Stay Updated
